SCHEMBL31139067

CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)O

nearest known ligand 0.73

Predicted protein targets (top 8)

	gene	UniProt	supporting neighbours	confidence
▸	CALCR	P30988	4/20	0.62

▸	CXCR4	P61073	1/20	0.59

▸	PTH1R	Q03431	7/20	0.58

▸	TFPI	P10646	3/20	0.56

▸	NPY1R	P25929	1/20	0.55

▸	NPY2R	P49146	1/20	0.55

▸	NPY4R	P50391	1/20	0.55

▸	NPY5R	Q15761	1/20	0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29939518	0.95	CALCR (0.58)	CALCRCXCR4PTH1RTFPINPY1R
SCHEMBL29407563	0.91	PTH1R (0.69)	CXCR4PTH1RTFPINPY1RNPY2R
SCHEMBL29895442	0.91	CALCR (0.73)	CALCRPTH1R
SCHEMBL6437853	0.91	CALCR (0.73)	CALCRPTH1R
SCHEMBL31182883	0.88	CXCR4 (0.60)	CALCRCXCR4TFPINPY1RNPY2R
SCHEMBL30668489	0.88	CALCR (0.63)	CALCRCXCR4TFPINPY1RNPY2R
SCHEMBL29489266	0.88	TFPI (0.64)	CALCRTFPINPY1RNPY2RNPY4R
SCHEMBL30887977	0.88	CALCR (0.64)	CALCRCXCR4PTH1RTFPI
SCHEMBL30495808	0.88	NPY2R (0.65)	CALCRTFPINPY1RNPY2RNPY4R
SCHEMBL30435977	0.88	CALCR (0.69)	CALCRTFPINPY1RNPY2RNPY4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12065512-B2	Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide	IGISU CO., LTD. (JP)	2024-08-20	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12065512-B2	Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide	TSLP, NPR1, VIP	CALCR 144/4885CXCR4 2299/4885PTH1R 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.